Drug Trial Radar · NCT07682818
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 18, 2026
Primary completion
Apr 12, 2027
Study completion Apr 12, 2027
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities. The aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.
Conditions
- Impaired Hepatic Function
Interventions
PetrelintideDrug
Petrelintide will be administered as a single SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Infinity (AUC0-inf) of PetrelintideTime frame: Day 1 (pre-dose) to Day 50 (Follow-up)
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.
Wroclaw, Poland, Poland · Recruiting
Summit Clinical Research s.r.o.
Bratislava, Bratislava Region, Slovakia · Recruiting
Summit Clinical Research s.r.o.
Malacky, Malacky, Slovakia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.